Lactose India Ltd Expands into Value-Added Pharmaceutical Excipients with ₹ 215 Crore Investment
Lactose India Ltd has adopted a new line of business in the pharmaceutical and healthcare raw materials / excipients industry. The company has invested approximately ₹ 215 crore towards plant & machinery, process development, and related infrastructure for value-added products, specifically specialised grades of pharmaceutical lactose. The new products include Spray Dried Lactose, Anhydrous Lactose, Homoeopathic Grade Lactose, and Inhalation Grade Lactose. These products are intended for the domestic pharmaceutical market, with potential to cater to international markets based on commercial feasibility and regulatory requirements. The company has successfully completed internal development and trial runs, with selective supplies to customers commencing in accordance with customer-specific validation and acceptance requirements.
Key Highlights
- Lactose India Ltd has expanded into value-added pharmaceutical excipients, specifically specialised grades of pharmaceutical lactose.
- The company has invested approximately ₹ 215 crore in the new line of business.
- The new products include Spray Dried Lactose, Anhydrous Lactose, Homoeopathic Grade Lactose, and Inhalation Grade Lactose.
- The products are intended for the domestic pharmaceutical market, with potential to cater to international markets based on commercial feasibility and regulatory requirements.
- The company has successfully completed internal development and trial runs, with selective supplies to customers commencing.